Under the agreement, Jubilant will develop early preclinical candidates
emanating from Amgen's early discovery efforts for an initial term of three
years. Amgen will have responsibility for the subsequent pre-clinical and
clinical development and commercialisation. Amgen will retain/own the
drugs developed under the collaboration with worldwide commercialisation rights.
The financial terms include a combination of research funding and
success-based milestones paid to Jubilant during pre-clinical and clinical
development for multiple projects undertaken by the collaboration. The total financial Milestone value is subject to successful development and
commercialisation of the portfolio of novel drugs.
Commenting on the development, Shyam S Bhartia, CMD and Hari S Bhartia, co-chairman and managing director of Jubilant Organosys said: "This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development, combining these
strengths with Amgen to deliver cost-effective new products that will help
patients around the world".
